Kura Oncology, Inc.
KURA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | -0.14 | -0.01 | 0.15 |
| FCF Yield | -10.73% | -5.98% | -12.52% | 35.41% |
| EV / EBITDA | -8.68 | -6.66 | -8.42 | -33.21 |
| Quality | ||||
| ROIC | -14.99% | -12.49% | -9.87% | -3.66% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 99.62% |
| Cash Conversion Ratio | 1.09 | 0.44 | 1.25 | -14.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 4,703,006.44% | 4,366,852.83% | 4,081,375.02% | 3,776,931.35% |
| Free Cash Flow Growth | -175.16% | 58.13% | -126.87% | 718.69% |
| Safety | ||||
| Net Debt / EBITDA | 1.01 | 1.05 | 0.49 | 12.53 |
| Interest Coverage | 203.55 | -185.85 | -169.37 | -55.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -636.52 | 310.97 | -637.90 |